(Updates)

** Shares of drug developer Keros Therapeutics fall ~77% to its lowest level of $15.96 since its Nasdaq debut in April 2020

** KROS says it has halted dosing of 3.0 mg per kg and 4.5 mg per kg doses of its high blood pressure treatment in a mid-stage study due to fluid buildup around the heart

** Dosing in the 1.5 mg/kg arm will continue after a risk-benefit review by an independent monitoring committee - KROS

** Co has notified the U.S. FDA about it and expects to present data from all treatment arms in Q2 2025 - KROS

** Including session's moves, stock has fallen 58.6% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))